At the news
? BULLISHIMPACT 5/10 PRESS-RELEASE filed Nov 12, 2026 at 17:00 ET
Regeneron announced positive Phase 2 PINNACLE trial results for baloncibart in POTS, showing a single 450 mg dose reduced heart rate upon standing and improved symptoms through four weeks. A potentially pivotal Phase 3 trial is planned for the first half of 2027. No FDA-approved treatments currently exist for POTS, which affects 500,000 to several million people in the U.S.
- Phase 2 PINNACLE trial evaluated single subcutaneous doses of baloncibart 150 mg (n=27) or 450 mg (n=28) vs placebo (n=27) in POTS patients.
- Baloncibart 450 mg reduced DeltaHR vs placebo at day 8 with LS mean difference of -11.4 bpm (nominal p=0.0007) and at day 29 with -7.4 bpm (nominal p=0.0124).
- Baloncibart 450 mg improved orthostatic symptoms, physical functioning, and activities of daily living vs placebo at day 29 per LWPQ.
- No FDA-approved treatments exist for POTS; potentially pivotal Phase 3 trial planned for first half of 2027.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access